Posted by Michael Wonder on 23 Apr 2024
FDA approves lutetium Lu 177 dotatate for paediatric patients 12 years and older with GEP-NETs
23 April 2024 - Today, the FDA approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications) for paediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours.
This represents the first FDA approval of a radioactive drug, or radiopharmaceutical, for paediatric patients 12 years of age and older with SSTR-positive GEP-NETs.
